Home ETF List About

Portfolio Holdings Detail for ISIN IE00BYXG2H39
Stock Name / FundiShares Nasdaq US Biotechnology UCITS ETF USD (Acc)
IssuerBlackrock
Entity holding fund iShares IV Public Limited Company
Entity TypeUmbrella investment company with variable capital and having segregated liability between its funds
Entity LEI 549300ZP07LMR36K1T02
ETF TickerBTEC(USD) LSE
ETF TickerBTEK(GBP) LSE
ETF Ticker2B70(EUR) F
ETF Ticker2B70.DE(EUR) CXE
ETF TickerBTEC.LS(USD) CXE
ETF TickerBTEK.LS(GBP) CXE
ETF TickerBTEC.L(GBP) LSE
ETF TickerBTEK.L(GBP) LSE

Holdings detail for KALV

Stock NameKalvista Pharmaceuticals Inc
TickerKALV(USD) NASDAQ
TYPECommon Stock
CountryUSA
ISINUS4834971032
LEI529900Q7IDA3WUGRZA51

Show aggregate KALV holdings

News associated with KALV

Brokerages Set KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Price Target at $26.43
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV – Get Free Report) has been given a consensus recommendation of “Buy” by the nine ratings firms that are currently covering the company, Marketbeat Ratings reports. Eight research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average 1-year […] - 2025-09-16 02:32:43
Brokerages Set KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Target Price at $26.29
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV – Get Free Report) has received an average recommendation of “Buy” from the nine brokerages that are currently covering the firm, Marketbeat reports. Eight equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 1-year price objective […] - 2025-08-22 02:58:49
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Shares Purchased by Bank of New York Mellon Corp
Bank of New York Mellon Corp boosted its position in shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV – Free Report) by 5.1% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 103,530 shares of the specialty pharmaceutical company’s stock after purchasing an additional […] - 2025-08-01 04:26:58
KalVista Pharmaceuticals (NASDAQ:KALV) Shares Up 5.5% After Analyst Upgrade
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV – Get Free Report) was up 5.5% during mid-day trading on Wednesday after JMP Securities raised their price target on the stock from $19.00 to $27.00. JMP Securities currently has a market outperform rating on the stock. KalVista Pharmaceuticals traded as high as $15.64 and last traded at $15.77. Approximately 354,539 […] - 2025-07-10 02:19:15
KalVista Pharmaceuticals (NASDAQ:KALV) Sets New 52-Week High on Analyst Upgrade
Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV – Get Free Report) hit a new 52-week high during mid-day trading on Tuesday after Leerink Partners raised their price target on the stock from $18.00 to $20.00. Leerink Partners currently has an outperform rating on the stock. KalVista Pharmaceuticals traded as high as $15.91 and last traded at […] - 2025-07-08 03:06:43
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Receives $24.83 Average Price Target from Analysts
Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV – Get Free Report) have been given an average recommendation of “Buy” by the eight research firms that are presently covering the company, Marketbeat.com reports. Seven research analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average […] - 2025-07-03 02:21:03
Stocks Rally as Iran Signals it Wants an End to Hostilities
The S&P 500 Index ($SPX ) (SPY ) is up +1.15%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +1.09%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +1.49%. June E-mini S&P futures (ESM25 ) are up +1.11%, and June E-mini Nasdaq futures (NQM25... - 2025-06-16 19:35:01
Stocks Rebound on Hopes Israel-Iran Conflict Will be Contained
The S&P 500 Index ($SPX ) (SPY ) is up +0.79%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +0.73%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.98%. June E-mini S&P futures (ESM25 ) are up +0.91%, and June E-mini Nasdaq futures (NQM25... - 2025-06-16 18:33:15
Stocks Rebound on Hopes Israel-Iran Conflict Will be Contained
The S&P 500 Index ($SPX ) (SPY ) is up +0.79%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +0.73%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.98%. June E-mini S&P futures (ESM25 ) are up +0.91%, and June E-mini Nasdaq futures (NQM25... - 2025-06-16 14:56:10
Stocks Rally as Iran Signals it Wants an End to Hostilities
The S&P 500 Index ($SPX ) (SPY ) is up +1.15%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +1.09%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +1.49%. June E-mini S&P futures (ESM25 ) are up +1.11%, and June E-mini Nasdaq futures (NQM25... - 2025-06-16 14:39:41
Stocks Rebound on Hopes Israel-Iran Conflict Will be Contained
The S&P 500 Index ($SPX ) (SPY ) is up +0.79%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +0.73%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.98%. June E-mini S&P futures (ESM25 ) are up +0.91%, and June E-mini Nasdaq futures (NQM25... - 2025-06-16 14:34:20
Stocks Rebound on Hopes Israel-Iran Conflict Will be Contained
The S&P 500 Index ($SPX ) (SPY ) is up +0.79%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +0.73%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.98%. June E-mini S&P futures (ESM25 ) are up +0.91%, and June E-mini Nasdaq futures (NQM25... - 2025-06-16 12:47:32
53,382 Shares in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Bought by Ameriprise Financial Inc.
Ameriprise Financial Inc. acquired a new position in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV – Free Report) during the 4th quarter, HoldingsChannel reports. The fund acquired 53,382 shares of the specialty pharmaceutical company’s stock, valued at approximately $452,000. Several other institutional investors also recently modified their holdings of the business. SG Americas Securities LLC grew its stake […] - 2025-06-05 04:22:54
ProShare Advisors LLC Purchases Shares of 11,906 KalVista Pharmaceuticals, Inc. (NASDAQ:KALV)
ProShare Advisors LLC purchased a new stake in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV – Free Report) in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 11,906 shares of the specialty pharmaceutical company’s stock, valued at approximately $101,000. Other hedge funds and other institutional investors also recently […] - 2025-06-04 04:54:43
Biotech Stocks Facing FDA Decision In June 2025
(RTTNews) - As May draws to a close, it's time to turn our attention to the FDA's upcoming slate of decisions. From January through May 2025, the U.S. regulatory agency has approved 13 novel drugs, a modest decline from the 16 approvals recorded during the same period in 2024. - 2025-05-30 06:02:12
Graham Capital Management L.P. Buys New Shares in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV)
Graham Capital Management L.P. bought a new stake in shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV – Free Report) in the 4th quarter, according to its most recent filing with the SEC. The institutional investor bought 10,479 shares of the specialty pharmaceutical company’s stock, valued at approximately $89,000. Several other large investors have also recently bought […] - 2025-05-20 05:10:56
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Receives $24.83 Average Target Price from Analysts
Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV – Get Free Report) have received a consensus recommendation of “Buy” from the eight brokerages that are presently covering the company, MarketBeat.com reports. Seven research analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month price […] - 2025-05-14 02:18:47
KalVista Pharmaceuticals (NASDAQ:KALV) and Verrica Pharmaceuticals (NASDAQ:VRCA) Critical Review
Verrica Pharmaceuticals (NASDAQ:VRCA – Get Free Report) and KalVista Pharmaceuticals (NASDAQ:KALV – Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, valuation, earnings, analyst recommendations, profitability and risk. Profitability This table compares Verrica Pharmaceuticals and […] - 2025-05-13 03:14:46
Dimensional Fund Advisors LP Has $5.90 Million Holdings in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV)
Dimensional Fund Advisors LP grew its position in shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV – Free Report) by 14.7% in the 4th quarter, Holdings Channel reports. The firm owned 696,037 shares of the specialty pharmaceutical company’s stock after acquiring an additional 89,001 shares during the quarter. Dimensional Fund Advisors LP’s holdings in KalVista Pharmaceuticals were […] - 2025-05-12 04:47:02
Legal & General Group Plc Acquires 1,494 Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV)
Legal & General Group Plc boosted its stake in shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV – Free Report) by 22.5% in the fourth quarter, Holdings Channel reports. The firm owned 8,144 shares of the specialty pharmaceutical company’s stock after acquiring an additional 1,494 shares during the period. Legal & General Group Plc’s holdings in KalVista […] - 2025-05-02 04:40:58
Marshall Wace LLP Purchases 103,072 Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV)
Marshall Wace LLP boosted its position in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV – Free Report) by 691.5% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 117,978 shares of the specialty pharmaceutical company’s stock after acquiring an additional 103,072 shares during the period. […] - 2025-05-01 04:52:57
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Shares Sold by Corebridge Financial Inc.
Corebridge Financial Inc. trimmed its position in shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV – Free Report) by 17.9% during the fourth quarter, HoldingsChannel reports. The fund owned 16,945 shares of the specialty pharmaceutical company’s stock after selling 3,682 shares during the quarter. Corebridge Financial Inc.’s holdings in KalVista Pharmaceuticals were worth $144,000 as of its […] - 2025-04-15 05:06:51
KalVista Pharmaceuticals (NASDAQ:KALV) Shares Up 8.3% – Should You Buy?
Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV – Get Free Report) rose 8.3% on Monday . The stock traded as high as $11.74 and last traded at $11.60. Approximately 531,267 shares traded hands during mid-day trading, an increase of 35% from the average daily volume of 392,121 shares. The stock had previously closed at $10.71. Analyst […] - 2025-04-08 04:36:53
Intech Investment Management LLC Raises Position in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV)
Intech Investment Management LLC lifted its stake in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV – Free Report) by 58.5% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 17,204 shares of the specialty pharmaceutical company’s stock after purchasing an additional 6,349 shares during the quarter. Intech […] - 2025-03-28 06:30:47
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Receives Average Rating of “Buy” from Analysts
Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV – Get Free Report) have earned an average recommendation of “Buy” from the eight analysts that are currently covering the firm, MarketBeat.com reports. Seven equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 1 […] - 2025-03-27 04:55:16
AlphaQuest LLC Acquires 2,588 Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV)
AlphaQuest LLC lifted its holdings in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV – Free Report) by 17.1% in the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 17,700 shares of the specialty pharmaceutical company’s stock after purchasing an additional 2,588 shares during the quarter. AlphaQuest LLC’s holdings in KalVista Pharmaceuticals were worth $150,000 at the end of […] - 2025-03-18 06:03:37
HC Wainwright Reaffirms Buy Rating for KalVista Pharmaceuticals (NASDAQ:KALV)
HC Wainwright reissued their buy rating on shares of KalVista Pharmaceuticals (NASDAQ:KALV – Free Report) in a research report released on Friday,Benzinga reports. The firm currently has a $20.00 price objective on the specialty pharmaceutical company’s stock. Several other equities research analysts have also weighed in on KALV. Bank of America began coverage on shares […] - 2025-03-17 04:12:56
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Sees Significant Drop in Short Interest
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV – Get Free Report) was the target of a significant decrease in short interest during the month of January. As of January 31st, there was short interest totalling 7,130,000 shares, a decrease of 6.1% from the January 15th total of 7,590,000 shares. Based on an average daily volume of 368,500 shares, […] - 2025-02-19 06:42:41
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Shares Bought by SG Americas Securities LLC
SG Americas Securities LLC grew its position in shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV – Free Report) by 10.0% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 14,508 shares of the specialty pharmaceutical company’s stock after purchasing an additional 1,319 shares […] - 2025-02-12 06:14:54
China Universal Asset Management Co. Ltd. Grows Stock Position in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV)
China Universal Asset Management Co. Ltd. increased its position in shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV – Free Report) by 24.7% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 10,329 shares of the specialty pharmaceutical company’s stock after buying an additional 2,043 shares […] - 2025-02-04 07:14:58

iShares Nasdaq US Biotechnology UCITS ETF USD (Acc) KALV holdings

DateNumber of KALV Shares HeldBase Market Value of KALV SharesLocal Market Value of KALV SharesChange in KALV Shares HeldChange in KALV Base ValueCurrent Price per KALV Share HeldPrevious Price per KALV Share Held
2025-11-11 (Tuesday)31,548USD 361,856USD 361,856
2025-11-10 (Monday)31,548KALV holding increased by 82USD 343,558KALV holding increased by 4355USD 343,55882USD 4,355 USD 10.89 USD 10.78
2025-11-07 (Friday)31,466USD 339,203KALV holding decreased by -3462USD 339,2030USD -3,462 USD 10.78 USD 10.89
2025-11-06 (Thursday)31,466KALV holding increased by 82USD 342,665KALV holding decreased by -2245USD 342,66582USD -2,245 USD 10.89 USD 10.99
2025-11-05 (Wednesday)31,384USD 344,910KALV holding increased by 7218USD 344,9100USD 7,218 USD 10.99 USD 10.76
2025-11-04 (Tuesday)31,384KALV holding increased by 82USD 337,692KALV holding decreased by -370USD 337,69282USD -370 USD 10.76 USD 10.8
2025-11-03 (Monday)31,302USD 338,062KALV holding decreased by -3443USD 338,0620USD -3,443 USD 10.8 USD 10.91
2025-10-31 (Friday)31,302USD 341,505KALV holding decreased by -1878USD 341,5050USD -1,878 USD 10.91 USD 10.97
2025-10-30 (Thursday)31,302KALV holding increased by 410USD 343,383KALV holding increased by 4807USD 343,383410USD 4,807 USD 10.97 USD 10.96
2025-10-29 (Wednesday)30,892KALV holding increased by 164USD 338,576KALV holding decreased by -3427USD 338,576164USD -3,427 USD 10.96 USD 11.13
2025-10-28 (Tuesday)30,728USD 342,003KALV holding decreased by -3072USD 342,0030USD -3,072 USD 11.13 USD 11.23
2025-10-27 (Monday)30,728USD 345,075KALV holding increased by 3072USD 345,0750USD 3,072 USD 11.23 USD 11.13
Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdings

Share Trades of KALV by Blackrock for IE00BYXG2H39

Show aggregate share trades of KALV

DateActionQuantityMarket HighMarket LowLikely Trade PriceLikely Trade Value (Profit/Loss)Average Price previous trades
2025-11-10BUY8211.10010.630 10.677USD 876 11.77
2025-11-06BUY8211.32010.765 10.821USD 887 11.78
2025-11-04BUY8211.04510.510 10.564USD 866 11.79
2025-10-30BUY41011.30010.915 10.953USD 4,491 11.80
2025-10-29BUY16410.96011.245 11.216USD 1,840 11.80
2025-10-22SELL-32811.13011.560 11.517USD -3,778 11.82 Profit of 100 on sale
2025-10-20BUY16411.54011.550 11.549USD 1,894 11.83
2025-10-17BUY40911.10011.280 11.262USD 4,606 11.83
2025-10-15BUY64811.94012.060 12.048USD 7,807 11.83
2025-10-03BUY57411.85011.930 11.922USD 6,843 11.83
2025-10-02BUY8211.75012.125 12.088USD 991 11.83
2025-09-30BUY16412.18012.360 12.342USD 2,024 11.83
2025-09-26BUY16412.40012.475 12.468USD 2,045 11.82
2025-09-25BUY16412.09512.480 12.441USD 2,040 11.82
2025-09-24SELL-2,19012.93013.275 13.240USD -28,997 11.82 Loss of -3,120 on sale
2025-09-18BUY8913.88013.910 13.907USD 1,238 11.80
2025-09-17BUY26713.38013.925 13.871USD 3,703 11.79
2025-08-20SELL-35212.91012.980 12.973USD -4,566 11.76 Loss of -427 on sale
2025-07-30BUY34813.84014.350 14.299USD 4,976 11.71
2025-07-17SELL-17416.01016.200 16.181USD -2,815 11.51 Loss of -812 on sale
2025-07-16BUY1,82115.79015.850 15.844USD 28,852 11.48
2025-07-11SELL-66414.52014.995 14.947USD -9,925 11.41 Loss of -2,347 on sale
2025-07-08BUY24914.95016.140 16.021USD 3,989 11.33
2025-07-02BUY4,56511.78012.000 11.978USD 54,680 11.29
2025-06-11BUY16613.46014.510 14.405USD 2,391 11.21
2025-06-10BUY16614.21014.870 14.804USD 2,457 11.19
2025-06-04SELL-8413.54013.570 13.567USD -1,140 11.10 Loss of -208 on sale
2025-04-23BUY8312.45012.690 12.666USD 1,051 10.73
2025-04-10SELL-66410.54010.750 10.729USD -7,124 10.62 Loss of -74 on sale
2025-04-08SELL-8310.32011.830 11.679USD -969 10.62 Loss of -88 on sale
2025-04-07SELL-8311.50011.735 11.711USD -972 10.61 Loss of -91 on sale
2025-04-04SELL-42010.71011.280 11.223USD -4,714 10.61 Loss of -258 on sale
2025-04-01BUY34411.15511.780 11.717USD 4,031 10.60
2025-03-31SELL-25211.54011.760 11.738USD -2,958 10.58 Loss of -291 on sale
2025-03-21BUY1,91511.89012.220 12.187USD 23,338 10.46
2025-03-14SELL-1,24812.60012.630 12.627USD -15,758 10.33 Loss of -2,868 on sale
2025-03-07SELL-15611.92012.195 12.167USD -1,898 10.19 Loss of -309 on sale
2025-03-04SELL-7811.27011.520 11.495USD -897 10.12 Loss of -107 on sale
2025-02-25BUY15610.77510.850 10.843USD 1,691 10.05
2025-02-19SELL-7810.71011.000 10.971USD -856 10.02 Loss of -74 on sale
2025-02-13BUY2349.5309.550 9.548USD 2,234 10.05
2025-02-12BUY789.3309.470 9.456USD 738 10.06
2025-02-11BUY3129.2709.300 9.297USD 2,901 10.08
2024-12-30SELL-3908.3908.520 8.507USD -3,318 10.55 Profit of 796 on sale
2024-11-18SELL-1,1559.3009.570 9.543USD -11,022 11.50 Profit of 2,256 on sale
2024-11-08SELL-7711.41011.410 11.410USD -879 11.56 Profit of 12 on sale
2024-10-21SELL-7812.32012.500 12.482USD -974 0.00 Loss of -974 on sale
Market high and low price is on the date.

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of KALV

DateShorted VolumeShort Exempt VolumeTotal Shares Traded% Shorted
2025-09-19206,7000312,45166.2%
2025-09-18106,1990217,39948.8%
2025-09-17100,4460161,75862.1%
2025-09-16200,9732,500330,07260.9%
2025-09-15132,995571274,74148.4%
2025-09-12491,71532,572973,25850.5%
2025-09-11725,69414,6241,135,07063.9%
2025-09-1071,3890381,25318.7%
2025-09-09156,9520445,09235.3%
2025-09-08256,6612,800530,26648.4%
2025-09-05152,8101,648357,61242.7%
2025-09-04245,9960580,69242.4%
2025-09-03197,5150776,02725.5%
2025-09-02176,1500408,11243.2%
2025-08-29100,6100148,05468.0%
2025-08-2880,4790135,74459.3%
2025-08-2767,5590106,06163.7%
2025-08-26121,9890170,44571.6%
2025-08-25143,1291,730191,90174.6%
2025-08-2286,3572,206174,73249.4%
2025-08-2199,83375159,09262.8%
2025-08-20113,4030182,67362.1%
2025-08-19126,9962,870196,51964.6%
2025-08-18286,3980390,85673.3%
2025-08-15133,756600239,98755.7%
2025-08-14276,6300366,91475.4%
2025-08-13133,2630225,86959.0%
2025-08-1288,7760158,55356.0%
2025-08-1178,111300127,29161.4%
2025-08-08126,588800213,00359.4%
2025-08-07103,660100200,45551.7%
2025-08-06119,0113226,30052.6%
2025-08-05110,819420196,22556.5%
2025-08-0493,1680205,31845.4%
2025-08-01115,6380232,98249.6%
2025-07-31130,3350211,77961.5%
2025-07-30178,3430324,54155.0%
2025-07-29227,2700421,97853.9%
2025-07-28272,4894,072819,27733.3%
2025-07-2588,9270488,23318.2%
2025-07-2480,047440229,91634.8%
2025-07-23245,1400575,37442.6%
2025-07-22134,483655231,99058.0%
2025-07-21119,61315,831216,13455.3%
2025-07-18142,5282,461517,06027.6%

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.